Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X.sub.1, X.sub.2, and X.sub.3 are N, and the remaining one of X.sub.1, X.sub.2, and X.sub.3 is --CR.sub.1; R.sub.1 is hydrogen or --CN; and N, G, Z, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.